Radiance Biopharma Secures Exclusive License for ROR-1 Antibody Drug Conjugate

BOSTON, MA, USA, February 19, 2025 - Radiance Biopharma, Inc., an emerging biotechnology company, has announced an exclusive licensing agreement with CSPC Megalith Biopharmaceutical Co., Ltd, a division of CSPC Pharmaceutical Group Limited. This agreement grants Radiance the rights to develop and commercialize RB-164 (SYS6005), an innovative antibody-drug conjugate (ADC) targeting the ROR-1 protein, across multiple regions including the USA, Canada, European Union, UK, and several other territories. CSPC will maintain the rights to SYS6005 in all other global markets.

ROR-1 is known for its significant expression in embryonic tissues and various cancers while being minimally present in healthy adult cells. Its strong association with cancer progression makes it an appealing target for cancer therapy. RB-164 harnesses a unique Fc-silenced monoclonal antibody directed at ROR-1. This method ensures a consistent drug-to-antibody ratio and high stability, offering a promising pharmacokinetic and toxicological profile.

The Chinese regulatory body, National Medical Products Administration (NMPA), has already approved the Investigational New Drug (IND) application for RB-164, allowing CSPC to conduct a Phase 1 clinical trial in China. This trial focuses on advanced liquid and solid tumors. Moving forward, Radiance and CSPC will collaborate to submit an IND application to the US FDA, with Radiance taking charge of the clinical development in the licensed territories.

Dr. Marc Lippman, Chairman of Radiance, expressed enthusiasm about the addition of RB-164 to the company's growing portfolio. He highlighted the ADC’s potential in addressing various therapeutic needs and reinforcing Radiance’s position in the biopharmaceutical sector.

Financial terms of the licensing agreement stipulate that Radiance will provide CSPC with an upfront payment of $15 million. Furthermore, CSPC stands to receive up to $150 million in development and regulatory milestones and over $1 billion in commercial milestone payments. Additionally, CSPC will earn tiered royalties commensurate with annual net sales.

Radiance’s CEO, Robert Brooks, emphasized the potential of RB-164 to become a leading ADC targeting the ROR-1 protein for treating both liquid and solid tumors. He anticipates this collaboration will expand Radiance’s pipeline, offering novel treatment options for cancer patients in dire need.

Zhang Cuilong, CEO of CSPC, remarked on the partnership with Radiance as a testament to CSPC’s dedication to delivering innovative treatments worldwide. He is optimistic about the potential of this ADC to serve as a new therapeutic option for cancer patients.

Radiance Biopharma is dedicated to developing antibody-based treatments for cancer, including both monospecific and bispecific ADCs. With a leadership team comprised of industry veterans like Dr. Marc Lippman and Dr. Martin Olivo, Radiance is actively pursuing advancements in oncology treatment.

CSPC Pharmaceutical Group is renowned for its prowess in drug research, development, manufacturing, and marketing. Established on the Hong Kong Stock Exchange, CSPC commands a significant presence in the pharmaceutical industry with a focus on innovative drug solutions ranging from small molecules to biological drugs across various research and development bases worldwide.